Biofrontera Inc.

Welcome to the BioFrontier, Inc. Third Quarter Earnings Conference Call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your question, please press star then two. Please note this event is being recorded. I would now like to turn the conference over to Pamela Keck, head of IR. Please go ahead.

Thank you, Matt. Good afternoon and welcome to BioFrontera Inc.' 's third quarter 2021 conference call. Please note that certain information discussed during today's call is covered under the safe harbor provisions of the Private Securities Litigation Reform Act. We caution listeners that BioFrontera's management will be making forward-looking statements. And that actual results may differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business. All risks and uncertainties are detailed in and are qualified by the cautionary statements contained in BioFrontera's press releases and SEC filings. This conference call contains time-sensitive information that is accurate only as of the date of the live broadcast. today, November 30th, 2021. BioFrontera undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call. During today's call, there will also be reference to certain non-GAAP financial measures. BioFrontera believes these measures provide useful information for investors. yet should not be considered as a substitute for GAAP, nor should they be viewed as a substitute for operating results determined in accordance with GAAP. A reconciliation of non-GAAP to GAAP results is included in this morning's press release. And with that, I would like to turn the call over to Hermann Lubritz, Executive Chairman of BioFrontier 8. Hermann, please go ahead.

Hermann Lubritz, Executive Chairman of BioFrontier 8 Thank you, Pamela, and good afternoon, everyone. Welcome to BioFrontera Inc.' 's first quarterly conference call. I would like to start the call with a brief background on BioFrontera Inc., which became a publicly traded company just about one month ago. BioFrontera Inc. was founded in 2015 as the U.S. commercial arm of the Germany-based parent company BioFrontera AG. To provide Biofrontera Inc. with the financial resources necessary to expand its marketing and sales activities, the parent company decided to allow an independent listing on Nasdaq. Our business rests on long-lasting, exclusive licenses to market and sell two prescription drugs in the United States. Both drugs serve multibillion-dollar accessible markets, And the listing allows raising the resources required to build marketing and sales within Biofrontera Inc. such that we can address these huge markets effectively. In addition, the listing on NASDAQ offers us the opportunity to flexibly exploit market opportunities or cover short-term financial needs, such as in the case of the recent 15 million private placement we announced yesterday. The future of the entire Biofrontera group clearly lies in the U.S. market, as this is where our products face the greatest commercial potential. Significantly increasing marketing and sales efforts here is therefore the cornerstone for successful corporate growth. As some of you may know, I am the founder of Biofrontera AG, the German parent company, and have been its CEO since inception. After originally agreeing to extend my term of office on the management board of Biofrontera AG until December 31st, 2022, I have now decided to remain at the disposal of the group for a further three years. However, I would like to devote these three years to where I see the greatest benefit for the entire group, the growth engine Biofrontera Inc. In view of the separation of the two Biofrontera companies I feel that I cannot effectively serve on both boards. Therefore, earlier this month, I submitted my request for early retirement as CEO and member of the management board of the supervisory board of Biofrontera AG. Once the supervisory board of Biofrontera AG has released me from my duties on the board of Biofrontera AG, I will fully devote myself to my duties as Executive Chairman of BioFrontera Inc. Joining me today is Erika Monaco, Chief Executive Officer of BioFrontera Inc. Erika will provide a more detailed overview over the business, our strategy, and our third quarter financial results. Erica has shown outstanding leadership and has been a key contributor to our success in the United States from the earliest stages, from the development of the business structure, processes, and partnerships required to operate and grow to the launch of our licensed products and our commercial success in the markets. With that, I'll turn the call over to Erica.